Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones: Prevalence results from the SENTRY antimicrobial surveillance program

Diagnostic Microbiology and Infectious Disease

Volumn 46, Issue 1, 2003, Pages 55-61

  Biedenbach, Douglas J ^a   Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GARENOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SITAFLOXACIN; SPARFLOXACIN; TROVAFLOXACIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONTROLLED STUDY; DILUTION; DRUG SENSITIVITY; GENE SEQUENCE; HAEMOPHILUS INFLUENZAE; HEALTH CENTER; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PUBLICATION; PULSED FIELD GEL ELECTROPHORESIS; REDUCTION; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE;

EID: 0038400090     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(03)00016-6     Document Type: Article

References (27)

1. Barriere S.L., Hindler J.A. Ciprofloxacin-resistant H. influenzae infection in a patient with chronic lung disease. Ann Pharmacother. 27:1993;309-310.
2. Bartlett J.G., Dowell S.F., Mandell L.A., File T.M. Jr, Musher D.M., Fine M.J. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 31:2000;347-382.
3. Bauernfiend A. Comparison of the antibacterial activities of the quinolones BAY 12-8039, gatifloxacin (AM1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother. 40:1997;639-651.
4. Biedenbach D.J., Jones R.N. Fluoroquinolone-resistant Haemophilus influenzae Frequency of occurrence and analysis of confirmed strains in the SENTRY Antimicrobial Surveillance Program (North and Latin America) . Diagn Microbiol Infect Dis. 36:2000;255-259.
5. Biedenbach D.J., Jones R.N., Pfaller M.A. Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States . Diagn Microbiol Infect Dis. 39:2001;245-250.
6. Blondeau J.M., Vaughan D., Laskowski R., Borsos S. Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae to oral antimicrobial agents. Int J Antimicrob Agents. 17:2001;457-464.
7. Bootsma H.J., Troelstra A., van Veen-Rutgers A., Mooi F.R., de Neeling A.J., Overbeek B.P. Isolation and characterization of a ciprofloxacin-resistant isolate of Haemophilus influenzae from The Netherlands. J Antimicrob Chemother. 39:1997;292-293.
8. Brueggemann A.B., Coffman S.L., Rhomberg P., Huynh H., Almer L., Nilius A., Flamm R., Doern G.V. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob Agents Chemother. 46:(3):2002;680-688.
9. Campos J., Roman F., Georgiou M., Garcia C., Gomez-Lus R., Canton R., Escobar H., Baquero F. Long-term persistence of ciprofloxacin-resistant Haemophilus influenzae in patients with cystic fibrosis. J Infect Dis. 174:1996;1345-1347.
10. Chen D.K., McGeer A., de Azavedo J.D., Low D.E. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med. 341:1999;233-239.
11. Corkill J.E., Percival A., McDonald P., Bamber A.I. Detection of quinolone resistance in Haemophilus spp. J Antimicrob Chemother. 34:1994;841-844.
12. Dipersio J.R., Jones R.N., Barrett T., Doern G.V., Pfaller M.A. Fluoroquinolone-resistant Moraxella catarrhalis in a patient with pneumonia Report from the SENTRY Antimicrobial Surveillance Program (1998) . Diagn Microbiol Infect Dis. 32:1998;131-135.
13. Felmingham D., Gruneberg R.N. The Alexander Project 1996-1997 Latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections . J Antimicrob Chemother. 45:2000;191-203.
14. Georgiou M., Munoz R., Roman F., Canton R., Gomez-Lus R., Campos J., de La Campa A. Ciprofloxacin-resistant Haemophilus influenzae strains possess mutations in analogous positions of gyr A and par C. Antimicrob Agents Chemother. 40:1996;1741-1744.
15. Gould I.M., Forbes K.J., Gordon G.S. Quinolone resistant Haemophilus influenzae. J Antimicrob Chemother. 33:1994;187-188.
16. Hoban D.J., Doern G.V., Fluit A.C., Roussel-Delvallez M., Jones R.N. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 32:(Suppl 2):2001;S81-S93.
17. Jones R.N. Fluoroquinolone (lomefloxacin) international surveillance trial A report of 30 months of monitoring in vitro activity . Am J Med. 92:(Suppl 4A):1992;52S-57S.
18. Jones R.N., Pfaller M.A. Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains Significant trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997-1999) . J Clin Microbiol. 38:2000;4298-4299.
19. Mandell L.A., Marrie T.J., Grossman R.F., Chow A.W., Hyland R.H. Canadian guidelines for the initial management of community-acquired pneumoniae An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracid Society . Clin Infect Dis. 31:2000;383-421.
20. Marco F., Garcia-de-Lomas J., Garcia-Rey C., Bouza E., Aguilar L., Fernandez-Mazarrasa C. Antimicrobial susceptibilities of 1,730 Haemophilus influenzae respiratory tract isolates in Spain in 1998-1999. Antimicrob Agents Chemother. 45:2001;3226-3228.
21. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically - Fifth Edition Approved standard M7-A5 . 2000;NCCLS, Wayne, PA.
22. Performance standards for antimicrobial disk susceptibility tests; Seventh edition Approved standard M2-A7 . 2000;NCCLS, Wayne, PA.
23. Performance standards for antimicrobial susceptibility testing; Twelfth informational supplement. M100-S12. 2002;NCCLS, Wayne, PA.
24. Nazir, J., Urban, C., Mariano, N., Burns, J., Segal-Maurer, S., & Rahal, J. J. (2002). Levofloxacin resistant Haemophilus influenzae in a long term care facility. In: Program and Abstracts of the 42nd Interscience Conference of Antimicrobial Agents and Chemotherapy, abst. #C2-647, p. 96. San Diego, CA, Sept. 27-30.
25. Niederman M.S., Mandell L.A., Anzueto A., Bass J.B., Broughton W.A., Campbell G.D., Dean N., File T., Fine M.J., Gross P.A., Martinez F., Marrie T.J., Plouffe J.F., Ramirez J., Sarosi G.A., Torres A., Wilson R., Yu V.L. Guidelines for the management of adults with community-acquired pneumoniae. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 163:2001;1730-1754.
26. Vila J., Ruiz J., Sanchez F., Navarro F., Mirelis B., Jimenez de Anta M.T., Prats G. Increase in quinolone resistance in a Haemophilus influenzae strain isolated from a patient with recurrent respiratory infections treated with ofloxacin. Antimicrob Agents Chemother. 43:1999;161-162.
27. Zhanel, G. G., Walkty, A., Nichol, K., Smith, H., Noreddin, A., Hoban, D. J. (2002). Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada. Diagn Microbiol Infect Dis, (in press).